ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-197678 | Pharmaceuticals and Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Oncolytic Virus Cancer Immunotherapy Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET
7.1 GLOBAL ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 AstraZeneca
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Amgen
16.3 F Hoffman-La Roche
16.4 Bristol-Myers Squibb
16.5 Novartis AG
16.6 Merck & Co. Inc.
16.7 Pfizer
16.8 Biovex
16.9 Cell Genesys
16.10 Crusade Laboratories
16.11 Genelux Corporation
16.12 Lokon Pharma
16.13 MultiVir
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeMonoclonal Antibodies
Checkpoint Inhibitors
Oncoloytic Viral Therapies and Cancer Vaccines
By Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and neck Cancer
Ovarian Cancer
Pancreatic Cancer
Companies
AstraZeneca
Amgen
F Hoffman-La Roche
Bristol-Myers Squibb
Novartis AG
Merck & Co. Inc.
Pfizer
Biovex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.